FDA accepts BLA for Pfizer’s haemophilia B gene therapy

Pfizer made the FDA and EMA submissions based on the safety and efficacy findings from the Phase III BENEGENE-2 study of fidanacogene elaparvovec. Credit: Pfizer Inc.